IL234686B - Methods of treating cancer by using Aurora Kinase inhibitors - Google Patents

Methods of treating cancer by using Aurora Kinase inhibitors

Info

Publication number
IL234686B
IL234686B IL234686A IL23468614A IL234686B IL 234686 B IL234686 B IL 234686B IL 234686 A IL234686 A IL 234686A IL 23468614 A IL23468614 A IL 23468614A IL 234686 B IL234686 B IL 234686B
Authority
IL
Israel
Prior art keywords
methods
treating cancer
kinase inhibitors
aurora kinase
aurora
Prior art date
Application number
IL234686A
Other languages
English (en)
Hebrew (he)
Other versions
IL234686A0 (en
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IL234686A0 publication Critical patent/IL234686A0/en
Publication of IL234686B publication Critical patent/IL234686B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL234686A 2012-03-20 2014-09-16 Methods of treating cancer by using Aurora Kinase inhibitors IL234686B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (2)

Publication Number Publication Date
IL234686A0 IL234686A0 (en) 2014-11-30
IL234686B true IL234686B (en) 2020-01-30

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
IL234686A IL234686B (en) 2012-03-20 2014-09-16 Methods of treating cancer by using Aurora Kinase inhibitors

Country Status (24)

Country Link
US (2) US20130303519A1 (OSRAM)
EP (1) EP2827855B1 (OSRAM)
JP (1) JP6373252B2 (OSRAM)
KR (1) KR102128866B1 (OSRAM)
CN (1) CN104271129A (OSRAM)
AU (1) AU2013235275B2 (OSRAM)
CA (1) CA2868024A1 (OSRAM)
EA (1) EA036434B1 (OSRAM)
ES (1) ES2746946T3 (OSRAM)
GE (1) GEP20186900B (OSRAM)
IL (1) IL234686B (OSRAM)
IN (1) IN2014DN08477A (OSRAM)
JO (1) JO3630B1 (OSRAM)
MA (1) MA37438A1 (OSRAM)
MX (1) MX358411B (OSRAM)
MY (1) MY175225A (OSRAM)
NZ (1) NZ700744A (OSRAM)
PH (1) PH12014502109A1 (OSRAM)
SG (2) SG10201607741RA (OSRAM)
TN (1) TN2014000387A1 (OSRAM)
TW (1) TWI649082B (OSRAM)
UA (1) UA117455C2 (OSRAM)
WO (1) WO2013142491A1 (OSRAM)
ZA (1) ZA201407551B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2016106357A1 (en) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
WO2017003845A1 (en) * 2015-07-02 2017-01-05 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式2−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
IL135303A0 (en) 1997-09-29 2001-05-20 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
CN100418955C (zh) 2001-08-09 2008-09-17 埃科特莱茵药品有限公司 新型苯并稠杂环
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AU2005213472A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
EP2261226B1 (en) 2004-05-14 2015-04-01 Millennium Pharmaceuticals, Inc. Methods for preparing aurora kinase inhibitors
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
CL2007000667A1 (es) 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
JP2010508353A (ja) 2006-10-31 2010-03-18 アキリオン ファーマシューティカルズ,インコーポレーテッド エルブシタビン薬学的組成物
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
KR102080429B1 (ko) 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2012140021A (ru) * 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
EP2827855B1 (en) 2019-06-26
AU2013235275A1 (en) 2014-10-23
TW201343169A (zh) 2013-11-01
IL234686A0 (en) 2014-11-30
US10213436B2 (en) 2019-02-26
US20130303519A1 (en) 2013-11-14
MX2014011324A (es) 2014-12-05
HK1206253A1 (en) 2016-01-08
GEP20186900B (en) 2018-10-10
TWI649082B (zh) 2019-02-01
PH12014502109A1 (en) 2014-12-10
US20160193224A1 (en) 2016-07-07
ZA201407551B (en) 2019-01-30
KR20140144215A (ko) 2014-12-18
MX358411B (es) 2018-08-20
SG10201607741RA (en) 2016-11-29
JP2015510945A (ja) 2015-04-13
EP2827855A1 (en) 2015-01-28
EA036434B1 (ru) 2020-11-10
EA201491727A1 (ru) 2015-01-30
CN104271129A (zh) 2015-01-07
CA2868024A1 (en) 2013-09-26
JO3630B1 (ar) 2020-08-27
JP6373252B2 (ja) 2018-08-15
MY175225A (en) 2020-06-16
ES2746946T3 (es) 2020-03-09
TN2014000387A1 (en) 2015-12-21
UA117455C2 (uk) 2018-08-10
NZ700744A (en) 2016-09-30
KR102128866B1 (ko) 2020-07-01
SG11201405621UA (en) 2014-10-30
MA37438A1 (fr) 2016-05-31
IN2014DN08477A (OSRAM) 2015-05-08
WO2013142491A1 (en) 2013-09-26
AU2013235275B2 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
ZA201402771B (en) Treatment of cancer with tor kinase inhibitors
IL237791A0 (en) A method for treating cancer
IL234639A0 (en) Cancer treatment with rapamycin target site kinase inhibitors
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
IL234641B (en) Cancer treatment with rapamycin target site kinase inhibitors
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
ZA201503105B (en) Treatment of prostate cancer with tor kinase inhibitors
PL2817286T3 (pl) Inhibitory kinazy do leczenia raka
ZA201407551B (en) Methods of treating cancer using aurora kinase inhibitors
IL237229A0 (en) Methods of treating cancer using lipoplatin
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed